Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Inhibition of ACAT in rat
Assay data:6 Active, 6 Activity ≤ 1 µM, 6 Tested
SummaryRelated BioAssays by Target
Inhibition of ACAT in human THP-1
Assay data:4 Active, 5 Activity ≤ 1 µM, 5 Tested
Inhibition of SOAT1 (unknown origin) expressed in CHO cells using [14C]oleic acid incubated for 6 hrs
Assay data:10 Active, 21 Tested
Inhibition of SOAT1 (unknown origin)
Assay data:4 Active, 2 Activity ≤ 1 µM, 5 Tested
Inhibition of african green monkey SOAT1 expressed in CHO cells assessed as reduction cholesteryl ester synthesis
Assay data:4 Active, 4 Tested
Inhibition of SOAT1 (unknown origin) expressed in CHO cells using [1-14C]oleic acid as substrate measured after 6 hrs
Assay data:1 Tested
Inhibition of human SOAT1 expressed in mouse AC29 cells
Assay data:3 Active, 1 Activity ≤ 1 µM, 5 Tested
Inhibition of human SOAT1
Assay data:1 Active, 1 Activity ≤ 1 µM, 1 Tested
Inhibition Assay from US Patent US9149492: "Method for selectively inhibiting ACAT1 in the treatment of alzheimer's disease"
Assay data:8 Active, 8 Activity ≤ 1 µM, 13 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by Target
ACAT-1 Enzyme Inhibition Assay from Article 10.1021/jm801507v: "Discovery of a potent, selective, and orally efficacious pyrimidinooxazinyl bicyclooctaneacetic acid diacylglycerol acyltransferase-1 inhibitor."
Assay data:1 Active, 7 Tested
SummaryCompounds, ActivePubMed CitationRelated BioAssays by DepositorRelated BioAssays by Target
Inhibitory Effect on ACAT2 Activity from US Patent US10278962: "Tricyclic analogues, preparation method and uses thereof"
Assay data:11 Active, 11 Activity ≤ 1 µM, 11 Tested
Inhibition of ACAT in mouse 3T3-L1 cells assessed as reduction in adiponectin expression level at 10 uM dosed during day 2 to 6 and followed by drug replacement every 48 hrs by LC-MS/MS analysis based proteomic analysis
Inhibition of ACAT in mouse 3T3-L1 cells assessed as reduction in hydroxy-steroid (17-beta) dehydrogenase 4 expression level at 10 uM dosed during day 2 to 6 and followed by drug replacement every 48 hrs by LC-MS/MS analysis based proteomic analysis
Inhibition of ACAT in mouse 3T3-L1 cells assessed as reduction in carnitine O-acetyltransferase expression level at 10 uM dosed during day 2 to 6 and followed by drug replacement every 48 hrs by LC-MS/MS analysis based proteomic analysis
Inhibition of ACAT in mouse 3T3-L1 cells assessed as reduction in acetyl-CoA acyltransferase 1 expression level at 10 uM dosed during day 2 to 6 and followed by drug replacement every 48 hrs by LC-MS/MS analysis based proteomic analysis
Inhibition of ACAT in mouse 3T3-L1 cells assessed as reduction in hydroxyacyl-CoA dehydrogenase expression level at 10 uM dosed during day 2 to 6 and followed by drug replacement every 48 hrs by LC-MS/MS analysis based proteomic analysis
Inhibition of ACAT in mouse 3T3-L1 cells assessed as reduction in enoyl CoA hydratase short chain 1 expression level at 10 uM dosed during day 2 to 6 and followed by drug replacement every 48 hrs by LC-MS/MS analysis based proteomic analysis
Inhibition of ACAT in mouse 3T3-L1 cells assessed as reduction in Acyl-CoA dehydrogenase expression level at 10 uM dosed during day 2 to 6 and followed by drug replacement every 48 hrs by LC-MS/MS analysis based proteomic analysis
Inhibition of ACAT in mouse 3T3-L1 cells assessed as reduction in FAS expression level at 10 uM dosed during day 2 to 6 and followed by drug replacement every 48 hrs by LC-MS/MS analysis based proteomic analysis
Inhibition of ACAT in mouse 3T3-L1 cells assessed as reduction in Acyl-CoA synthetase long-chain family member 1 expression level at 10 uM dosed during day 2 to 6 and followed by drug replacement every 48 hrs by LC-MS/MS analysis based proteomic analysis
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on